Prev Arrow Stocks

IDEXX Laboratories Inc. ($IDXX) Stock Forecast: Up 5.0% Today

Morpher AI identified a bullish signal. The stock price may continue to rise based on the momentum of the good news.

What is IDEXX Laboratories Inc.?

IDXX (Idexx Laboratories) is a leading provider of veterinary diagnostic solutions, offering a range of tests for the detection of diseases in animals. The company has a strong market presence and is known for its innovative products and services.

Why is IDEXX Laboratories Inc. going up?

IDXX stock is up 5.0% on Nov 21, 2025 18:51

  • IDXX stock experienced a strong bullish movement today, breaking out above the 20-day moving average, indicating positive momentum.
  • The news about Molina (MOH) securing a deal to serve Florida's Medicaid members is unrelated to IDXX's bullish movement.
  • Investors may have reacted positively to the breakout above the moving average, signaling potential upside for IDXX in the near term.
  • The breakout could be a result of increased investor confidence in the company's growth prospects and continued demand for its veterinary diagnostic solutions.

IDXX Price Chart

IDXX Technical Analysis

IDXX News

Idexx Laboratories ( IDXX ) Recently Broke Out Above the 20-Day Moving Average

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

https://www.zacks.com/stock/news/2793597/idexx-laboratories-idxx-recently-broke-out-above-the-20-day-moving-average

0 Missing News Article Image Idexx Laboratories  ( IDXX )  Recently Broke Out Above the 20-Day Moving Average

Molina Secures Deal From AHCA to Serve Florida's Medicaid Members

MOH wins sole contract from AHCA to manage care for around 120,000 Florida enrollees of SMMC and CHIP through a Medicaid deal.

https://www.zacks.com/stock/news/2792152/molina-secures-deal-from-ahca-to-serve-floridas-medicaid-members

1 Missing News Article Image Molina Secures Deal From AHCA to Serve Florida's Medicaid Members

IDEXX Laboratories Inc. Price History

21.07.2024 - IDXX Stock was down 0.6%

  • The downward trend in IDXX today may be due to the following reasons:
  • Profit-taking: Investors who have realized substantial profits from holding IDXX stock for an extended period may have opted to sell shares to secure their gains, resulting in a decrease in the stock price.
  • Market correction: Following a period of sustained success, IDXX might be undergoing a natural market correction as investors review their positions and explore new investment prospects.
  • External influences: Economic conditions or industry-related developments could also be impacting the bearish movement in IDXX today, prompting investors to modify their investment portfolios accordingly.

30.00.2025 - IDXX Stock was up 5.2%

  • IDXX's upturn today is linked to market expectations of robust Q4 earnings, attributed to the company's successful execution of strategic initiatives.
  • Investors are positive about IDXX's outlook, anticipating growth and profitability in the upcoming period.
  • The favorable outlook for IDXX mirrors the market's confidence in the company's capability to deliver value and sustain a competitive position in the veterinary diagnostics sector.

03.10.2025 - IDXX Stock was up 1.5%

  • Expectations are high for IDEXX Laboratories' upcoming release of Q3 earnings, with analysts predicting an increase in quarterly earnings compared to the previous year. This optimistic forecast likely played a role in the recent bullish movement in the stock.
  • Over the past decade, IDXX has demonstrated impressive long-term performance, consistently outperforming the market and delivering substantial returns for investors. This consistent track record could be attracting more interest from investors.
  • A Hershey analyst's shift in sentiment towards IDEXX Laboratories, no longer holding a bearish view, combined with other top analyst upgrades, may be bolstering investor confidence in the company's future prospects and contributing to the current bullish trend in the stock.

03.10.2025 - IDXX Stock was up 0.1%

  • IDXX stock witnessed a notable upturn today after announcing impressive Q3 earnings that surpassed expectations, along with an optimistic future forecast.
  • The company disclosed adjusted earnings of $3.22 per share, marking a 15% year-over-year increase and exceeding analyst estimates.
  • Analysts had predicted earnings of $3.14 per share, underscoring confidence in the company's ability to deliver robust financial results.
  • Top Wall Street analysts have upgraded their outlook on IDXX, reflecting an increasing bullish sentiment among investors.

31.09.2024 - IDXX Stock was down 9.5%

  • Third-quarter earnings of IDXX surpassed adjusted EPS predictions but fell short of revenue consensus, hinting at possible hurdles in revenue expansion.
  • The deceleration in revenue growth is possibly linked to a decline in veterinary visits, influencing the company's sales trajectory.
  • Noteworthy growth in segments such as CAG and Water was eclipsed by the lower-than-expected revenue, possibly instigating a downward trend in the stock's value.
  • Concerns among investors about IDXX's future growth sustainability are palpable, with guidance adjustments contributing to the stock's market decline.

01.04.2025 - IDXX Stock was up 9.0%

  • IDEXX Laboratories has showcased an average annual return of 21.28% over the past 10 years.
  • The company boasts a market capitalization of $35.41 billion, indicating its market strength and resilience.
  • Today, IDXX experienced a bullish movement likely attributed to its consistent growth and robust financial performance that has attracted investors seeking high returns.

01.04.2025 - IDXX Stock was up 9.0%

  • Strong Q1 earnings were reported by IDXX, surpassing expectations and resulting in an increased outlook for the fiscal year 2025. This positive financial performance has led to heightened investor interest and a rise in the stock price.
  • Over the past decade, IDXX has consistently outperformed the market, achieving an impressive annualized return of 21.28%. This track record has likely fostered investor confidence in the company's future growth prospects.
  • The notable financial results and a history of market-beating returns have fueled a positive trend in IDXX stock, reflecting optimistic investor attitudes and confidence in the company's future prospects.

04.07.2025 - IDXX Stock was up 4.2%

  • IDEXX reported strong Q2 earnings, surpassing expectations with earnings of $3.50 per share and revenue reaching $1.11 billion.
  • The impressive 11% growth in Companion Animal Group sales contributed to the revenue increase, showcasing the company's strong performance in its core business segment.
  • The raised full-year EPS guidance and revenue forecast indicate a positive outlook for IDEXX, reassuring investors and justifying the premium valuation of the stock.
  • Overall, the market responded positively to IDEXX's robust financial results and optimistic future prospects, driving the stock price higher.

21.10.2025 - IDXX Stock was up 5.0%

  • IDXX stock experienced a strong bullish movement today, breaking out above the 20-day moving average, indicating positive momentum.
  • The news about Molina (MOH) securing a deal to serve Florida's Medicaid members is unrelated to IDXX's bullish movement.
  • Investors may have reacted positively to the breakout above the moving average, signaling potential upside for IDXX in the near term.
  • The breakout could be a result of increased investor confidence in the company's growth prospects and continued demand for its veterinary diagnostic solutions.

31.06.2025 - IDXX Stock was down 5.1%

  • Despite high expectations for Q2 earnings with anticipated growth in various segments, IDXX experienced a strong bearish movement today.
  • The market may have reacted negatively to the actual earnings release, which potentially fell short of the optimistic forecasts.
  • Investors might have been disappointed by certain aspects of the earnings report, such as lower-than-expected revenue or guidance for future performance.
  • It's possible that profit-taking or market dynamics unrelated to the company's fundamentals also contributed to the bearish movement in IDXX's stock price today.

06.07.2024 - IDXX Stock was up 5.3%

  • Following the impressive second-quarter results, IDXX stock demonstrated a bullish trend, surpassing estimates for both EPS and revenue.
  • The favorable earnings report, highlighted by exceeding EPS forecasts and revenue growth, likely enhanced investor confidence in the company's performance and future outlook.
  • Despite lowering its FY24 guidance in a separate update, the market primarily responded to the strong quarterly results, propelling a bullish sentiment in IDXX stock.
  • The failure to meet earnings and revenue projections in a different statement did not notably sway market sentiment towards IDXX today, as attention remained focused on the positive quarterly showing.

05.07.2025 - IDXX Stock was down 5.6%

  • IDEXX Laboratories (IDXX) stock experienced a bearish movement despite surpassing earnings expectations and posting strong Q2 results.
  • The market may have reacted negatively due to profit-taking by investors after a period of growth following the positive earnings report.
  • Despite the positive news of revenue growth, EPS beat, and raised guidance, the stock might have been impacted by broader market trends or sector rotation.
  • Investors might be cautious about the stock's valuation or potential future challenges despite the company's strong performance.
i
Disclaimer
Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.